Currently Viewing:
Currently Reading
Biomarkers to Distinguish Psoriatic Arthritis Prove Elusive, Study Says
May 30, 2020 – Mary Caffrey
Practical Insights on the Changing Spectrum of Biologic Agents for the Treatment of Patients With Psoriatic Disease
May 23, 2020 – An Interview With Jerry Bagel, MD
Psoriasis Guidelines From AAD, NPF Spotlight Comorbidities
May 08, 2020 – Skylar Jeremias
Researchers Track Improvements in Rare Pediatric Liver Disease Through Biomarker
April 25, 2020 – Skylar Jeremias
Study Outlines Incidence of Comorbidities Among Migraineurs
March 30, 2020 – Gianna Melillo
Report Finds Natural Clusters of Chronic Migraine Phenotypes
March 10, 2020 – Gianna Melillo
Study Finds Smell, Taste Impaired in Patients With Wolfram Syndrome
March 02, 2020 – Gianna Melillo
PAPER OF THE WEEK: The Links Between Metabolic Syndrome and Mental Illness
February 15, 2020 – Mary Caffrey
Migraineurs Exhibit Comorbidities Spanning ICD-10 Spectrum
February 03, 2020 – Gianna Melillo

Biomarkers to Distinguish Psoriatic Arthritis Prove Elusive, Study Says

Mary Caffrey
Catching psoriatric arthritis (PsA) early has been a challenge even when the diagnosis is aided by sonography, according to the authors.
Rheumatologists who have been looking for serological markers to distinguish psoriatric arthritis (PsA) from psoriasis may have to continue their hunt, based on results appearing this week in Clinical Rheumatology.

Catching PsA early has been a challenge even when the diagnosis is aided by sonography, according to the authors. The difficulty shows up in the literature, such as a 2018 study that discussed the need to reclassifying patients with psoriasis as having PsA once their symptoms progressed. Yet finding and treating PsA early is essential to avoid disability.

“The under-diagnosis of PSA among persons with psoriasis not only delays treatment but also increases the risk of joint damage,” they wrote. “In one study, the rate of PSA under-diagnosis was estimated to be about 9%. Early diagnosis of PSA could also increase awareness in doctors to treat comorbidities.”

The authors retrospectively analyzed serological markers and comorbidities in 629 psoriatic patients, including 102 with PsA; the others had psoriasis. The serological markers were not useful (P > .05 for all comparisons). Prevalence of PsA among the psoriasis patients was 19.4%.

According to the study, the team found no early warning for PsA after testing for total leukocyte count, platelets, hemoglobin, hematocrit, lipoprotein profile, inflammation markers (C-reactive protein, erythrocyte sediment rate), titers of anti-nuclear antibodies, or rheumatoid factor.

Comorbidities proved more useful. Metabolic syndrome-hyperlipidemia (2.94%) and gout (4.9%) were significantly more prevalent in those with PsA than those with psoriasis (P < .05). The odds ratio (OR) for PsA is 15.94 in patients with hyperlipidemia (95% CI, 1.64-154.80). The OR for PSA is 3.83 in those with gout (95% CI, 1.19-12.31).

Allergic rhinitis was more prevalent (5.88%) in patients with PsA than patients with psoriasis (P < .01); The OR  was 8.17 (95% CI, 2.26-29.50). One possible biomarker, plasma hs-miR-210-3p, separates PsA from psoriasis and can be detected even after treatment with anti-tumor necrosis factor-α agents (P < .05).


Su Y. Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin Rheumatol. Published online May 28, 2020. doi:10.1007/s10067-020-05132-1

Related Articles

Psoriasis and Psoriatic Arthritis Overview
Psoriatic Arthritis Leads to Higher Costs, Absenteeism, Studies Say
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up